^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DST (Dystonin)

    i
    Other names: DST, Dystonin, BP240, BPA, KIAA0728, CATX-15, MACF2, BPAG1, Hemidesmosomal Plaque Protein, Bullous Pemphigoid Antigen 1, Dystonia Musculorum Protein, Bullous Pemphigoid Antigen, FLJ21489, FLJ13425, FLJ32235, FLJ30627, DMH, DT, Bullous Pemphigoid Antigen 1, 230/240kDa, 230/240 KDa Bullous Pemphigoid Antigen, 230 KDa Bullous Pemphigoid Antigen, Trabeculin-Beta, D6S1101, CATX15, EBSB2, HSAN6, BP230, EBS3
    Associations

    News

    Trials
    over1year
    DST regulates cisplatin resistance in colorectal cancer via PI3K/Akt pathway. (PubMed, J Pharm Pharmacol)
    DST plays a crucial role in limiting CRC progression and overcoming DDP resistance, suggesting potential for targeted CRC therapies.
    Journal
    |
    DST (Dystonin)
    |
    cisplatin
    over2years
    A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors. (PubMed, Hum Cell)
    Of two CDX and six clinical samples of OS and Ewing's sarcoma, DST identified proteasome inhibitors (bortezomib, carfilzomib) and CEP-701 as potentially effective drugs in common. This unique method of in vitro drug testing using 3D-cell cultures is feasible in surgically resected tissues of metastatic malignant bone tumors.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • mTOR (Mechanistic target of rapamycin kinase) • DST (Dystonin)
    |
    PIK3CA mutation • MTOR mutation
    |
    bortezomib • carfilzomib • lestaurtinib (CEP-701)
    almost3years
    Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes. (PubMed, Nat Commun)
    The drug-targetable alanyl-tRNA synthetase (AARS1) in the high tumor mutation burden/immune infiltration is significantly enhanced in DC progression, and catalyzes the lysine-alanylation of poly-ADP-ribose polymerases (PARP1), which decreases the apoptosis of cancer cells, eventually promoting cell proliferation and tumorigenesis. We assess the proteogenomic landscape of early DC, and provide insights into the molecular features corresponding therapeutic targets.
    Journal • Tumor mutational burden • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • DST (Dystonin)
    |
    TMB-H • MTOR mutation